Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Biohaven Pharmaceutical Holding Company Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HAVEN, CONN., JULY 27, 2026 /PRNEWSWIRE/ -- BIOHAVEN LTD.

FEDERAL JURY FINDS AVILAR THERAPEUTICS AND RA CAPITAL WILLFULLY AND MALICIOUSLY MISAPPROPRIATED TRADE SECRET DEVELOPED AT YALE, AWARDS BIOHAVEN AND YALE UNIVERSITY $4 MILLION

BIOHAVEN ALSO ANNOUNCES NEW CLINICAL SUPPLY AGREEMENT WITH REGENERON TO EVALUATE BHV-1530 IN COMBINATION WITH CEMIPLIMAB (LIBTAYO) EARLY CLINICAL ACTIVITY OBSERVED: PHASE 1 DOSE-ESCALATION DATA SHOW EARLY TUMOR REDUCTIONS IN PATIENTS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR)3-ALTERED AND WILD-TYPE OVEREXPRESSING TUMORS. SIGNAL ACTIVITY INCLUDING CONFIRMED PARTIAL RESPONSES IN HEAVILY PRETREATED PATIENTS IN MULTIPLE TUMOR TYPES.

BIOHAVEN TO PRESENT NEW CLINICAL DATA AT ESMO CONGRESS ON BHV-1530, A NOVEL FGFR3-DIRECTED ADC WITH A PROPRIETARY TOPOISOMERASE I (TOPOIX) PAYLOAD

DAVID PIRMAN, PH.D. PROMOTED TO EXECUTIVE VICE PRESIDENT AND HEAD OF DISCOVERY BRUCE CAR, PH.D.

BIOHAVEN ANNOUNCES SCIENTIFIC LEADERSHIP TRANSITIONS

ENROLLMENT COMPLETE IN PIVOTAL PHASE 2/3 STUDY EVALUATING OPAKALIM IN FOCAL EPILEPSY (RISE3); TOP-LINE RESULTS ON TRACK FOR 2H 2026 EMERGING OPAKALIM FOCAL EPILEPSY AND IDIOPATHIC GENERALIZED EPILEPSY DATA PRESENTED AT RECENT R&D DAY REINFORCE EVIDENCE OF TARGET ENGAGEMENT, POTENTIAL FOR EFFICACY, AND DIFFERENTIATED TOLERABILITY PROFILE IN THE ONGOING FOCAL EPILEPSY OPEN-LABEL EXTENSION (OLE) STUDY, 54% OF PARTICIPANTS ON OPAKALIM 75 MG ONCE-DAILY ACHIEVED A 50% REDUCTION IN SEIZURE FREQUENCY COMPARED TO PRE-RANDOMIZATION BASELINE, WITH A MARKEDLY LOWER INCIDENCE OF NERVOUS SYSTEM ADVERSE EVENTS COMPARED TO APPROVED AND INVESTIGATIONAL ASMS HIGH DOUBLE-BLIND COMPLETION RATES OF ~95%, AND HIGH ROLLOVER RATES INTO THE OLE OF ~95%, REFLECT FAVORABLE PATIENT EXPERIENCE WITH OPAKALIM NEW HAVEN, CONN., JUNE 30, 2026 /PRNEWSWIRE/ -- BIOHAVEN LTD.

BIOHAVEN COMPLETES ENROLLMENT IN RISE 3 PIVOTAL FOCAL EPILEPSY STUDY WITH OPAKALIM, A SELECTIVE KV7.2/7.3 ACTIVATOR

BHV-1300 IS THE FIRST MODE EXTRACELLULAR PROTEIN DEGRADER TO ENTER A PIVOTAL TRIAL, PIONEERING A NEW CLASS OF PRECISION IMMUNOLOGY MEDICINES THAT ELIMINATE THE DISEASE-DRIVING ANTIBODIES AT THE ROOT OF AUTOIMMUNE DISEASE. BHV-1300 TARGETS THE TSHR-IGG1 AUTOANTIBODY THAT DRIVES GRAVES' DISEASE, NOT THE THYROID GLAND ITSELF.

BIOHAVEN ADVANCES A NEW CLASS OF PRECISION IMMUNOLOGY THERAPIES: FIRST MODE EXTRACELLULAR PROTEIN DEGRADER, BHV-1300, BEGINS PHASE 3 PIVOTAL TRIAL IN GRAVES' DISEASE

BHV-8100 IS AN ORALLY ADMINISTERED, BRAIN-PENETRANT PKM2 MODULATOR; A NOVEL THERAPEUTIC CLASS ADDRESSING THE BIOENERGETIC AND IMMUNOMETABOLIC BASIS OF SYSTEMIC AND CENTRAL NERVOUS SYSTEM DISORDERS FIRST-IN-HUMAN STUDY INITIATED WITH DOSE ESCALATION ONGOING; PRELIMINARY DATA IN HEALTHY PARTICIPANTS DEMONSTRATES FAVORABLE PHARMACOKINETICS SUPPORTING CONVENIENT, ONCE-DAILY DOSING AND WELL A TOLERATED PROFILE AT PROJECTED THERAPEUTIC EXPOSURES PENETRATES BLOOD-BRAIN BARRIER AND REVERSES METABOLIC DYSFUNCTION WITH 3-FOLD IMPROVEMENT IN GLUCOSE UTILIZATION IN HUMAN, WHOLE BRAIN MODEL (BEXORG BRAINEX PLATFORM, PHYSIOLOGICALLY REACTIVATED BRAINS FROM HUMAN DONORS); PREFERENTIAL METABOLIC RESCUE IN ALZHEIMER'S DISEASE DONOR BRAINS VS CONTROLS EXHIBITS ROBUST BENEFICIAL EFFECTS ACROSS A SPECTRUM OF PRECLINICAL MODELS OF ALZHEIMER'S, AND MULTIPLE SCLEROSIS: RESTORES METABOLIC DEFICITS, REDUCES INFLAMMATION AND NEURODEGENERATION, AND ENHANCES REMYELINATION PKM2 MODULATION OFFERS A POTENTIAL NEW PARADIGM FOR TREATING LARGE, UNDERSERVED, AND HIGH-VALUE INDICATIONS IN NEUROLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY NEW HAVEN, CONN., JUNE 1, 2026 /PRNEWSWIRE/ --BIOHAVEN LTD.

BIOHAVEN REPORTS FIRST-IN-HUMAN DOSING OF ORAL PKM2 MODULATOR, BHV-8100, TARGETING METABOLIC RESTORATION AND IMMUNOMODULATION

BHV-1300 DEMONSTRATED DEEP, RAPID, AND SUSTAINED LOWERING OF PATHOGENIC TSHR AUTOANTIBODIES (TSHR-IGG1) IN PATIENTS WITH GRAVES' HYPERTHYROIDISM RECEIVING 1000 MG SC WEEKLY, WITH MEAN REDUCTIONS IN TSHR-IGG1EXCEEDING >80% OVER THE 12-WEEK STUDY. PARTICIPANTS WITH GRAVES' OVERT HYPERTHYROIDISM, CONFIRMED BY ELEVATED BASELINE THYROID TESTS DESPITE BEING TREATED WITH ANTI-THYROID DRUG THERAPY (ATD), EXPERIENCED NORMALIZATION OF THYROID HORMONES WITHIN WEEKS; T4 NORMALIZATION OCCURRING AT A MEDIAN OF 3 WEEKS AND T3 AT A MEDIAN OF 5 WEEKS AFTER THE FIRST ADMINISTRATION OF BHV-1300.

BIOHAVEN REPORTS POSITIVE CLINICAL BIOMARKER AND PATIENT DATA: FIRST MODE AND TRAP EXTRACELLULAR PROTEIN DEGRADERS ACHIEVE DEEP, RAPID, SELECTIVE LOWERING OF DISEASE-DRIVING ANTIBODIES IN GRAVES' DISEASE AND IGA NEPHROPATHY

IN A RANDOMIZED, PLACEBO-CONTROLLED, TIME-TO-EVENT TRIAL IN IDIOPATHIC GENERALIZED EPILEPSY (IGE), THE MEDIAN TIME TO THE SECOND DAY WITH A GENERALIZED TONIC-CLONIC SEIZURE WAS 141 DAYS IN THE OPAKALIM 75 MG ONCE-DAILY TREATMENT GROUP VS. 47 DAYS IN THE PLACEBO GROUP, REPRESENTING A 3-FOLD PROLONGATION.

BIOHAVEN REPORTS NEW CLINICAL DATA IN EPILEPSY WITH OPAKALIM, A SELECTIVE KV7.2/7.3 ACTIVATOR, HIGHLIGHTING SEIZURE CONTROL AND MARKEDLY DIFFERENTIATED TOLERABILITY PROFILE

BIOHAVEN TO UPDATE CLINICAL, REGULATORY, AND OPERATIONAL PROGRESS AT ANNUAL R&D DAY AT THE UPCOMING YALE INNOVATION SUMMIT ON MAY 27, 2026. ADVANCEMENT OF HIGH-VALUE, LATE-STAGE PRIORITY PROGRAMS: PIVOTAL EPILEPSY PROGRAM WITH SELECTIVE KV7 ION CHANNEL ACTIVATOR, OPAKALIM, WITH EXPECTED TOPLINE RESULTS IN 2H 2026.

BIOHAVEN REPORTS RECENT BUSINESS DEVELOPMENTS AND FIRST QUARTER 2026 FINANCIAL RESULTS

PHASE 2 STUDY IN OBESITY, EVALUATING TREATMENT WITH ONCE-WEEKLY AND ONCE-MONTHLY TALDEFGROBEP ALFA AS MONOTHERAPY, IS NOW FULLY ENROLLED; TOPLINE DATA EXPECTED IN 2H 2026. TALDEFGROBEP IS A NOVEL INHIBITOR OF THE MYOSTATIN-ACTIVIN SIGNALING PATHWAY, WHICH DIRECTLY TARGETS BOTH FAT AND MUSCLE, OFFERING THE POTENTIAL TO ACHIEVE HIGH-QUALITY WEIGHT LOSS IN PEOPLE LIVING WITH OVERWEIGHT AND OBESITY.

Biohaven Pharmaceutical Holding Company Ltd.

BHVN

Price

Financial Reports

No items found.

Press Releases

Biohaven Pharmaceutical Holding Company Ltd.

BHVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHVN